Skip to content
HowShorted

REATA PHARMACEUTICALS INC short interest in 2022

In 2022, REATA PHARMACEUTICALS INC's disclosed short interest ran from 10.62% of shares outstanding on 14 Jan 2022 to 21.77% on 30 Dec 2022, a change of +11.15 percentage points. The year's high was 21.77% on 30 Dec 2022 and its low 6.64% on 28 Feb 2022, averaging 13.67% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 22.94 days on 29 Jul 2022. Full history: REATA PHARMACEUTICALS INC.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023

Aggregate net short position time series for REATA PHARMACEUTICALS INC in 2022

2022 in figures

Start of year
10.62% (14 Jan 2022)
End of year
21.77% (30 Dec 2022)
Change
+11.15 pp
High
21.77% (30 Dec 2022)
Low
6.64% (28 Feb 2022)
Average
13.67%
Highest days to cover
22.94 (29 Jul 2022)
SEC filings marked
8

Every report in 2022

REATA PHARMACEUTICALS INC short interest in 2022
SettlementShort interestDays to coverFilings since previous
14 Jan 202210.62%5.43
31 Jan 20228.10%4.27
15 Feb 20226.88%4.64
28 Feb 20226.64%3.1910-K filed, results (8-K)
15 Mar 20229.31%5.83
31 Mar 202210.42%3.45
14 Apr 202212.61%9.42
29 Apr 202213.96%9.54
13 May 202213.70%9.7110-Q filed, results (8-K)
31 May 202212.81%9.10
15 Jun 202213.49%11.59
30 Jun 202213.75%11.17
15 Jul 202213.78%15.33
29 Jul 202213.85%22.94
15 Aug 202212.90%4.5210-Q filed, results (8-K)
31 Aug 202211.46%4.69
15 Sep 202213.57%3.19
30 Sep 202214.09%8.40
14 Oct 202214.62%6.55
31 Oct 202218.17%6.14
15 Nov 202219.91%8.3610-Q filed, results (8-K)
30 Nov 202221.71%15.87
15 Dec 202219.96%18.20
30 Dec 202221.77%18.29

See also: REATA PHARMACEUTICALS INC's full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.